Literature DB >> 16189418

A comparative study of goblet cell and pancreatic exocine autoantibodies combined with ASCA and pANCA in Chinese and Caucasian patients with IBD.

Ian Craig Lawrance1, Anne Hall, Rupert Leong, Callum Pearce, Kevin Murray.   

Abstract

BACKGROUND: The incidence of Crohn's disease (CD) and ulcerative colitis (UC) is increasing, but differentiating between them is often extremely difficult. Pancreatic (PAB) and goblet cell autoantibodies (GAB) are specific for CD and UC, respectively, but with low sensitivity. In combination with anti-Saccharomyces cerevisiae (ASCA) and anti-neutrophil cytoplasmic antibodies (pANCA) testing, these antibodies may improve differentiation between the diseases. This study determined the sensitivity, specificity, and positive and negative predictive values (PPV and NPV) of PAB and GAB +/- ASCA and pANCA testing in Chinese and Caucasian IBD populations.
RESULTS: Patients were recruited from Caucasian and Chinese populations (CD, n = 100; UC, n = 99; controls, n = 100). PAB was highly specific for CD, and detection was greater in patients less than 35 years old and in Chinese compared with Caucasian patients with CD (CD, 46% versus 22%, P = 0.018; UC, 2% versus 6%; controls, 0% versus 2%). GAB detection was poor in all groups (<2%). PAB showed a PPV of 93% to differentiate all patients with CD from patients with UC, but only 62% for those with isolated colonic disease. The PPV of PAB increased to 100%, specificity was 100%, and sensitivity was 21% for isolated colonic disease when combined with pANCA and ASCA. PAB expression was not associated with stricturing or perforating CD.
CONCLUSIONS: This study identified that GAB was not useful in our patients with IBD. PAB expression was highly specific for CD and more sensitive in Chinese than Caucasian patients with CD. The combination of PAB, pANCA, and ASCA testing improved the differentiation between UC and CD, particularly in isolated colonic disease, compared with pANCA and ASCA testing alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16189418     DOI: 10.1097/01.mib.0000182872.76434.8c

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  Clinical significance of inflammatory markers.

Authors:  Bincy P Abraham; Selvi Thirumurthi
Journal:  Curr Gastroenterol Rep       Date:  2009-10

2.  Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives.

Authors:  Huseyin Demirsoy; Kamil Ozdil; Ozdal Ersoy; Besir Kesici; Cetin Karaca; Canan Alkim; Nihat Akbayir; Levent Kamil Erdem; Mehmet Derya Onuk; Hulya Tugrul Beyzadeoglu
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 3.  Utility of serological markers in inflammatory bowel diseases: gadget or magic?

Authors:  Maria Papp; Gary L Norman; Istvan Altorjay; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

4.  Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study.

Authors:  S Desplat-Jégo; C Johanet; A Escande; J Goetz; N Fabien; N Olsson; E Ballot; J Sarles; J J Baudon; J C Grimaud; M Veyrac; P Chamouard; R L Humbel
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

Review 5.  Antibody markers in the diagnosis of inflammatory bowel disease.

Authors:  Keiichi Mitsuyama; Mikio Niwa; Hidetoshi Takedatsu; Hiroshi Yamasaki; Kotaro Kuwaki; Shinichiro Yoshioka; Ryosuke Yamauchi; Shuhei Fukunaga; Takuji Torimura
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 6.  Serological markers of inflammatory bowel disease.

Authors:  Andrea Tesija Kuna
Journal:  Biochem Med (Zagreb)       Date:  2013       Impact factor: 2.313

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.